The VIL1 antibody targets Villin-1. a 92.5 kDa actin-binding protein critical for maintaining cytoskeletal structure and cell motility. Primarily expressed in epithelial cells of the gastrointestinal tract (e.g., intestinal enterocytes, kidney proximal tubules), Villin-1 regulates actin filament assembly, microvilli formation, and cell polarity. Its expression is often tissue-specific, making it a valuable biomarker for identifying intestinal or renal epithelial lineages in research and diagnostics.
VIL1 antibodies are widely used in immunohistochemistry (IHC), immunofluorescence (IF), and Western blotting to study epithelial differentiation, cellular injury, or neoplastic transformations. In cancer research, Villin-1 overexpression is linked to gastrointestinal adenocarcinomas, while its loss may indicate dedifferentiation. These antibodies also aid in distinguishing carcinomas of intestinal origin from other malignancies.
Commercially available VIL1 antibodies (e.g., monoclonal clones like CWWB1) are validated for specificity across human and rodent models. However, staining patterns may vary depending on fixation methods or epitope accessibility. Recent studies explore Villin-1's role beyond structure—such as in signal transduction and apoptosis—highlighting its broader relevance in epithelial pathophysiology. Overall, VIL1 antibodies remain essential tools in epithelial biology and translational oncology.
(Word count: 199)